ReviewThe FEBS journal2013
Harnessing the genome for characterization of G-protein coupled receptors in cancer pathogenesis.
Review in The FEBS journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 34 citations in OpenAlex.
- A targetable opioid/cancer associated fibroblast axis drives extracellular matrix remodeling and tumor aggressiveness in pancreatic cancer.bioRxiv : the preprint server for biology · 2026Article
- PARInternational journal of molecular sciences · 2025Article
- Targeting F2R/PAR1 with ligand decorated lipid nanocarriers for enhanced drug delivery into ovarian cancer cells.Frontiers in drug delivery · 2025Article
- PAR-Induced Harnessing of EZH2 to β-Catenin: Implications for Colorectal Cancer.International journal of molecular sciences · 2022Article
- GPR120 prevents colorectal adenocarcinoma progression by sustaining the mucosal barrier integrity.Scientific reports · 2022Article
- Review
- Unintended Effects of GPCR-Targeted Drugs on the Cancer Phenotype.Trends in pharmacological sciences · 2020Review
- Elevated expression of GNAS promotes breast cancer cell proliferation and migration via the PI3K/AKT/Snail1/E-cadherin axis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2019Article
- Transcriptional Landscape of PARs in Epithelial Malignancies.International journal of molecular sciences · 2018Review
- Integrated molecular analysis of Tamoxifen-resistant invasive lobular breast cancer cells identifies MAPK and GRM/mGluR signaling as therapeutic vulnerabilities.Molecular and cellular endocrinology · 2018Article
- GPCRomics: GPCR Expression in Cancer Cells and Tumors Identifies New, Potential Biomarkers and Therapeutic Targets.Frontiers in pharmacology · 2018Article
- A new insight into identification of in silico analysis of natural compounds targeting GPR120.Network modeling and analysis in health informatics and bioinformatics · 2018Article
- RGS19 upregulates Nm23-H1/2 metastasis suppressors by transcriptional activation via the cAMP/PKA/CREB pathway.Oncotarget · 2017Article
- Article
- Growth inhibition of human breast carcinoma cells by overexpression of regulator of G-protein signaling 4.Oncology letters · 2017Article
- An in vivo screening system to identify tumorigenic genes.Oncogene · 2017Article
- Analysis of the interplay between methylation and expression reveals its potential role in cancer aetiology.Functional & integrative genomics · 2017Article
- G-protein-coupled receptor 81 promotes a malignant phenotype in breast cancer through angiogenic factor secretion.Oncotarget · 2016Article
- G Protein-Coupled Receptors in Cancer.International journal of molecular sciences · 2016Review
- Protease-Activated Receptors and other G-Protein-Coupled Receptors: the Melanoma Connection.Frontiers in genetics · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
G-protein coupled receptors (GPCRs) mediate numerous physiological processes and represent the targets for a vast array of therapeutics for diseases ranging from depression to hypertension to reflux. Despite the recognition that GPCRs can act as oncogenes and tumour suppressors by regulating oncogenic signalling networks, few drugs targeting GPCRs are utilized in cancer therapy. Recent large-scale genome-wide analyses of multiple human tumours have uncovered novel GPCRs altered in cancer. However, work aiming to determine which GPCRs from these lists are the drivers of tumourigenesis, and hence valid therapeutic targets, comprises a formidable challenge. The present review highlights recent studies providing evidence that GPCRs are relevant targets for cancer therapy through their effects on known cancer signalling pathways, tumour progression, invasion and metastasis, and the microenvironment. Furthermore, the review also explores how genomic analysis is beginning to highlight GPCRs as therapeutic targets in the age of personalized medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.